Literature DB >> 20632063

AL amyloidosis with IgD-lambda monoclonal gammopathy and lambda-type Bence-Jones protein: successful treatment by autologous stem cell transplantation.

Chanhyok Sakurai-Chin1, Yoshifumi Ubara, Tatsuya Suwabe, Junichi Hoshino, Tomoki Yonaha, Eiko Hasegawa, Keiichi Sumida, Rikako Hiramatsu, Masayuki Yamanouchi, Noriko Hayami, Junji Yamauchi, Naoyuki Tominaga, Naoki Sawa, Fumi Takemoto, Kazuhiro Masuoka, Kenmei Takaichi, Kenichi Oohashi.   

Abstract

A 45-year-old Japanese woman had been diagnosed with monoclonal gammopathy of undetermined significance (MGUS) featuring urinary Bence-Jones protein of the lambda type (BJP-lambda) for 11 years. She then developed eyelid purpura, dyspnea, and flank pain. Abdominal CT scans revealed renal infarction. Biopsy of the kidney, heart, jejunum, and skin demonstrated amyloid deposits in the vessel walls, but not in the glomeruli. She was diagnosed as having AL amyloidosis with IgD-lambda monoclonal gammopathy and BJP-lambda. Autologous stem cell transplantation (SCT) was done after chemotherapy with vincristine, daunorubicin, dexamethasone (VAD), and high-dose melphalan (HDM). This reduced the IgD level from 156 to 0.1 mg/dL, along with the disappearance of BJP, despite cerebral infarction during chemotherapy. We recommend SCT for patients with IgD-associated AL amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20632063     DOI: 10.1007/s10157-010-0311-2

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  26 in total

Review 1.  An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Authors:  V Sanchorawala; D G Wright; D C Seldin; L M Dember; K Finn; R H Falk; J Berk; K Quillen; M Skinner
Journal:  Bone Marrow Transplant       Date:  2001-10       Impact factor: 5.483

2.  Primary amyloidosis presenting as renal infarction.

Authors:  M Arias; J A Abreu; A Iglesias; J Longo; F Lecumberri; F Vega
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

Review 3.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

4.  Amyloidosis: review of 236 cases.

Authors:  R A Kyle; E D Bayrd
Journal:  Medicine (Baltimore)       Date:  1975-07       Impact factor: 1.889

5.  VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection.

Authors:  Takahisa Gono; Masayuki Matsuda; Yasuhiro Shimojima; Wataru Ishii; Jun Koyama; Kazuo Sakashita; Kenichi Koike; Yoshinobu Hoshii; Shu-ichi Ikeda
Journal:  Amyloid       Date:  2004-12       Impact factor: 7.141

6.  High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Authors:  Jolanta B Perz; Stefan O Schonland; Michael Hundemer; Arnt V Kristen; Thomas J Dengler; Martin Zeier; Reinhold P Linke; Anthony D Ho; Hartmut Goldschmidt
Journal:  Br J Haematol       Date:  2004-12       Impact factor: 6.998

7.  [Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases].

Authors:  S Mseddi-Hdiji; S Haddouk; M Ben Ayed; N Tahri; M Elloumi; S Baklouti; J Hachicha; M S Krichen; Z Bahloul; H Masmoudi
Journal:  Pathol Biol (Paris)       Date:  2005-02

8.  Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases.

Authors:  J Bladé; J A Lust; R A Kyle
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

9.  High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Authors:  Arnaud Jaccard; Philippe Moreau; Veronique Leblond; Xavier Leleu; Lotfi Benboubker; Olivier Hermine; Christian Recher; Bouchra Asli; Bruno Lioure; Bruno Royer; Fabrice Jardin; Frank Bridoux; Bernard Grosbois; Jérome Jaubert; Jean-Charles Piette; Pierre Ronco; Fabrice Quet; Michel Cogne; Jean-Paul Fermand
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245

10.  Primary systemic amyloidosis with ischemic stroke as a presenting complication.

Authors:  Alexander Y Zubkov; Alejandro A Rabinstein; Angela Dispenzieri; Eelco F M Wijdicks
Journal:  Neurology       Date:  2007-09-11       Impact factor: 9.910

View more
  1 in total

1.  The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.

Authors:  Dosuke Iwadate; Eiko Hasegawa; Junichi Hoshino; Noriko Hayami; Keiichi Sumida; Masayuki Yamanouchi; Akinari Sekine; Masahiro Kawada; Rikako Hiramatsu; Tatsuya Suwabe; Naoki Sawa; Mitsuhiro Yuasa; Atsushi Wake; Takeshi Fujii; Kenichi Ohashi; Kenmei Takaichi; Yoshifumi Ubara
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.